On Thursday, Piper Jaffray analysts raised the price target on shares of Chimerix Inc (NASDAQ: CMRX) to $37 from $33 and maintained an Overweight rating.

In light of the current Ebola concerns, Piper Jaffray analysts believe that Chimerix is the top Ebola play.

Joshua Schimmer finds that “Chimerix’s drug Brincidofovir is “an “attractive option” for government stockpiling, not only as potential treatment for Ebola but also for smallpox.”

Moreover, analysts noted, “A drug needs to show activity in two animal species, human safety to qualify for stockpiling; CMRX may be able to satisfy safety requirement with CMV program.”

Shares of Chimerix recently traded at $29.25, up 0.45 percent.